State-of-the-art genetics panel optimizes kidney disease treatment
Answers from the Lab
Genetic factors play a role in at least 10% of adult cases of kidney disease and up to 70% of cases in children. In this test specific episode of the "Answers From the Lab" podcast, Linnea M. Baudhuin, Ph.D., and Emily K. Thoreson, M.S., CGC, explain how Mayo Clinic Laboratories renal genetics testing provides comprehensive and accurate results for optimal patient care.
"Our tests are among the most comprehensive diagnostic tests available. They utilize next generation sequencing for maximum depth of coverage and the highest possible detection rates across 302 genes, including technically challenging genes," Dr. Baudhin says.
The testing can identify potential underlying genetic causes of kidney disease and the specific type of kidney disease a patient has. "The results can then be used to guide treatment, inform prognosis and assess family members' risk," Thoreson says.
Unlike competitors' screening tests, Mayo Clinic Laboratories' panels are diagnostic. "You can trust them to identify an actual medical condition," Dr. Baudhin says. "Screening tests require clinical confirmation. The actual implications of the results are harder to understand."
Listen to learn more about Mayo Clinic Laboratories' renal genetics panel.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.
Melissa Snyder, Ph.D., explains how Mayo Clinic Laboratories' EDN panel improves the evaluation of certain patients with asthma and autoimmune digestive disorders. EDN is the first laboratory test that provides a marker of eosinophil-derived neurotoxins.
Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation sequencing and complements the laboratory's cell-based cancer testing.